Impax Laboratories, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and marketing generic and branded products. Impax Generics includes the company’s legacy Global Pharmaceuticals business as well as the acquired CorePharma and Lineage Therapeutics businesses. Impax Specialty Pharma includes the legacy Impax Pharmaceuticals business as well as the acquired Amedra Pharmaceuticals business. Impax’s Generics Division focuses on a broad range of therapeutic areas, including products having technically challenging drug-delivery mechanisms or unique product formulations. In addition to developing solid oral dosage products, the company’s portfolio includes alternative dosage form products, primarily through alliance and collaboration agreements with third parties. The Company’s Specialty Pharma Division is focused on the development and promotion, through the company’s specialty sales force, of proprietary branded pharmaceutical products for the treatment of Central Nervous System disorders and other select specialty segments. The Impax Specialty Pharma Division currently has one internally developed branded pharmaceutical product, RYTARY (IPX066), an extended-release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, postencephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication.

Show more
Type
Public
HQ
Hayward, US
Founded
1999
Size (employees)
1,495 (est)
Impax Laboratories was founded in 1999 and is headquartered in Hayward, US
Report incorrect company information

Impax Laboratories Office Locations

Impax Laboratories has offices in Fort Washington, Hayward, Philadelphia, Chalfont and in 1 other location
Hayward, US (HQ)
30831 Huntwood Ave
Chalfont, US
121 New Britain Blvd
Philadelphia, US
3735 Castor Ave
Zhunan Township, TW
No. 1, Ke Dong 3rd Road Jhunan Science Park Miaoli County 350
Show all (5)
Report incorrect company information

Impax Laboratories Financials and Metrics

Impax Laboratories Financials

Impax Laboratories's revenue was reported to be $824.43 m in FY, 2016 which is a 4.2% decrease from the previous period.
USD

Revenue (Q1, 2018)

142.4 m

Gross profit (Q1, 2018)

30.3 m

Gross profit margin (Q1, 2018), %

21.3%

Net income (Q1, 2018)

(130.9 m)

EBIT (Q1, 2018)

(124.9 m)

Market capitalization (4-May-2018)

1.4 b

Closing share price (4-May-2018)

18.3

Cash (31-Mar-2018)

104.2 m

EV

2 b
Impax Laboratories's current market capitalization is $1.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

511.5 m596 m860.5 m824.4 m

Revenue growth, %

17%44%(4%)

Cost of goods sold

312.2 m283.4 m508.1 m

Gross profit

199.3 m312.7 m352.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

132.6 m118.7 m188.1 m158 m143.1 m214.2 m221.1 m225.5 m172.6 m227.9 m184.4 m202.1 m142.4 m

Cost of goods sold

84.3 m61.1 m78.3 m73.6 m83.9 m129.3 m127.6 m122.9 m99.6 m136.9 m120.2 m129.7 m112.1 m

Gross profit

48.3 m57.6 m109.8 m84.4 m59.2 m84.9 m93.5 m102.6 m73 m91 m64.2 m72.4 m30.3 m

Gross profit Margin, %

36%49%58%53%41%40%42%45%42%40%35%36%21%
Annual
USDFY, 2013FY, 2014FY, 2015

Cash

184.6 m214.9 m340.4 m

Accounts Receivable

113 m146.5 m324.5 m

Inventories

12.7 m33.7 m31.7 m

Current Assets

659.7 m730.5 m822.1 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

190.3 m318.4 m412.2 m366.8 m232.1 m157.3 m171.4 m104.2 m

Accounts Receivable

241.7 m228.5 m214.4 m237.5 m239.6 m214 m219.7 m226.4 m

Inventories

123.4 m130.3 m133.6 m148.1 m167.6 m195.6 m200.4 m158.6 m

Current Assets

703 m797.8 m782.4 m776.7 m700.6 m593.9 m628.5 m577.7 m
Annual
USDFY, 2013FY, 2014FY, 2015

Net Income

101.3 m57.4 m39 m

Depreciation and Amortization

36 m34 m68.6 m

Inventories

7.1 m(24 m)(5.9 m)

Accounts Payable

4.7 m(9 m)48.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

110.9 m6.4 m41.5 m57.2 m(6.3 m)(8.2 m)27.6 m(10.4 m)(13.1 m)(192.4 m)(98.4 m)(118.8 m)(130.9 m)

Depreciation and Amortization

30.5 m8 m16.3 m24.6 m10.4 m30.7 m48.7 m15.7 m36.4 m63.1 m25.8 m54 m18 m

Inventories

(13.8 m)(6.5 m)(25.4 m)(19.3 m)(4.9 m)(6.1 m)(8.8 m)(20 m)(33.6 m)(50.5 m)(19.2 m)(23.1 m)2.5 m

Accounts Payable

22.1 m(26.2 m)6.3 m13.6 m(1.6 m)(20.1 m)(5.5 m)2.2 m(13.3 m)31.8 m806 k21.4 m8.8 m
USDY, 2018

EV/EBIT

-16.3 x

EV/CFO

-23.8 x

Financial Leverage

20.5 x
Show all financial metrics
Report incorrect company information